HelioLiver LDT now available to order through Quest Diagnostics
Parminder Bhatia joins the Helio Genomics Board to advance AI-driven cancer diagnostics
News & Media

Third News: Parminder Bhatia Joins Helio’s Board to Advance AI Diagnostics

In the News Jul 16, 2026 2 min read Via Third News
Share

Helio Genomics has strengthened its Board of Directors with the addition of Parminder (Parry) Bhatia, a widely recognized artificial-intelligence leader, in a move aimed at accelerating its mission to detect cancer earlier. As a California-based company specializing in AI-enhanced precision diagnostics for liver cancer, Helio sees the appointment as a strategic step toward advancing its early-detection technology and widening its impact on patient care.

Bhatia serves as Senior Vice President of Artificial Intelligence at Edwards Lifesciences, where he has concentrated on building responsible AI frameworks inside a highly regulated healthcare setting. He previously held the role of Chief AI Officer at GE HealthCare, driving AI strategy across medical devices and software, and earlier contributed to healthcare AI and machine-learning work at Amazon, Microsoft and Georgia Tech. His achievements have earned recognition from Modern Healthcare’s 40 Under 40 and Constellation Research, and he holds a computer science degree from the Indian Institute of Technology along with a machine-learning-focused master’s from Georgia Tech.

For Helio’s leadership, the appointment is about the road ahead. CEO Dr. Bharat Tewarie said Bhatia’s leadership and innovative approach to AI will be critical as the company scales its work to improve early cancer detection worldwide. Bhatia, for his part, pointed to the value of combining artificial intelligence with multiomic data to sharpen tools such as HelioLiver — the company’s blood test for the early detection of hepatocellular carcinoma — and, ultimately, to improve outcomes for patients.

Helio Genomics develops blood-based diagnostics that apply machine learning and deep learning to identify cancer biomarkers, giving clinicians faster, clearer information to act on. With Bhatia helping to integrate complex biological and clinical signals, the company expects to extend its reach across precision medicine, disease monitoring and treatment response — potentially reshaping how cancer is detected and managed in the years ahead.

Read the Full Article

Source: Third News. Read the full article.

Related Articles

More from Helio Genomics

In the NewsJul 16, 2026

360Dx: Parminder Bhatia Appointed to Helio Genomics’ Board

360Dx reports Helio has appointed Parminder Bhatia, SVP of AI at Edwards Lifesciences, to its board of directors.

Read more
Press ReleaseJul 16, 2026

PR Newswire: Healthcare AI Leader Parminder Bhatia Joins Helio Board

The official announcement: Helio appoints Parminder Bhatia, SVP of AI at Edwards Lifesciences, to its Board of Directors.

Read more
PodcastJul 14, 2026

Apple Podcasts: Why AI + Multiomics Will Replace Liver Cancer Ultrasound

Helio CEO Bharat Tewarie on the Diagnosing Dx podcast on moving liver cancer screening beyond ultrasound.

Read more